NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases ...

Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Technology, Oil & Gas and Utilities sectors led shares higher. At the close in NYSE, the Dow ...

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price target of $41.00. The company’s shares closed last ...

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK - Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company focused on developing treatments for cancer and rare diseases, has initiated a public ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and ...

Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Sell-side analysts expect that Viridian Therapeutics will post -4.03 earnings per share for ...